

C h a n n e l M a n a g e m e n t

Finnish diagnostic companies in DACH region
Webinar – 6th October 2021

Christine Grumbach, Senior Business Developer, EurAsiaGrowth



EurAsiaGrowth

Consulting-Training-Services

Overview Medical Diagnostics

Non apparatus-based

Anamnesis (questions, talks)

Medical inspection

Palpation

Auscultation / Percussion

Apparatus-based diagnostics

Radiology

CT, MRT, PET

Sonography (Ultrasound)

Functional tests (ECG, spirometry,
blood pressure, pulse oximetry...)


Endoscopy

Laboratory diagnostics


IT-Supported diagnostics (health apps, telemedicine, AI)




Similarities and differences in Germany,
Austria and Switzerland



Channel management intro




Examples of successful
distributor models






Relevant issues for market entry



POC, new customer segments,
private large cooperations




How to manage DACH
region distributors with
success? Do's and don'ts




European medical technology market ca. 140 billion € in 2020

Medical device market by country




IVD market by country




Source: The European Medical Technology Industry in figures, 2021

Channel partners rely on the suitability of the diagnostics to the national funding schemes!



Source: OECD Health Statistics 2020; Eurostat Database; WHO Global Health Expenditure Database

The major part of diagnostics is connected to out-patient care !




* Refers to curative-rehabilitative care in inpatient and day care settings. ** Includes home care and ancillary services and can be provided in ambulatory care settings or hospitals.

Source: OECD Health Statistics 2020; Eurostat Database;

Hospitals in the DACH region are less involved in outpatient diagnostics!

Hospital expenditures by type of service, 2018



*Refers to curative-rehabilitative care provided to outpatients or at their homes and ancillary services.


**Refers to inpatient LTC services for people with LTC needs.

***Includes medical goods and collective health services.

Source: OECD Health Statistics 2020; Eurostat Database.

Diagnostics are essential in prevention but not all countries put the same focus on it!

Spending on primary health care services as share of total health spending, 2018




Additional providers of prevention are:

1. Health insurers
2. Occupational health
3. High-end diagnostic service centers (\$ OOP)

Source: OECD Health Statistics 2020;


Lack of GPs and unequal distribution of specialists leads to challenges in diagnostic services and care!



1. Other generalists include non-specialist doctors working in hospital and recent medical graduates who have not started yet their post-graduate specialty training.

Source: OECD Health Statistics 2020; Eurostat Database.

Ratio of nurses to doctors, 2018 (or nearest year)




Source: OECD Health Statistics 2019; Swiss data from Eurostat Database 2020.

Efficient sales and service channels are expected to avoid additional workload for the clients!



Number of doctor consultations per person, 2018 (or nearest year)



Estimated number of consultations per doctor

2296

1939

1259


1310

1101

Source: OECD Health Statistics 2020; Eurostat Database.


Channel partners must provide access to the key clients for the diagnostics!

Health expenditure by provider, 2018




Source: OECD Health Statistics 2020; Eurostat Database

CT, MRI or PET exams per 1000 population, 2018 (or nearest year)



Source: OECD Health Statistics 2020; Eurostat Database.


Impact of COVID-19 on various medtech sectors



Source: The European Medical Technology Industry in figures, 2021




European medical device growth rates



Source: The European Medical Technology Industry in figures, 2021



European IVD market growth rates



2020

Total diagnostics 25,9%

Reagents total 28,1%

- Clinical chemistry – 15,5%
- Immuno chemistry – 2,1%
- Haematology/Histol/Cyt. -3,6%
- Microbiology (Culture) – 5,8%
- **Infectious Diseases 291,4 %**
- Genetic Testing 1,1%

Instrument/Consumables 17,5%

Services/Spare Parts 3,5%

Sources:

The European Medical Technology Industry in figures, 2021

VDGH, Working group Market Research, 2021






02


Channel management intro



Channel management starts with channel selection



Typical channel structure options diagnostic devices







03

Examples of successful distributor models



Cardio pulmonary, metabolic and body composition diagnostic equipment for professional users





medisana. Specialist home health care market incl. diagnostics





Business Concept

Contract R&D +
manufacturing + external
products under one brand
and brands of licence
partners

Headquarter in Germany (Marburg)

B2C

25 quick tests:

Fertility, prevention,
allergy, food
intolerance

8 food supplements:

8 products (brand:
alphabiol)

Starting 2021:

SARS-CoV-2 antigen
for consumers

Suppliers

- Azure Biotech INC
- BTNX Inc.
- Labnovation Technologies Inc
- Nantong Diagnos Ltd.

National

Licence partners



MIGROS

International

25 Distributors

B2B

Infectious diseases:

HIV-Quick; Strep-A,
Influenza AB

Prevention:

Troponin I; D-Dimer;
Microalbumin

Starting 2020:

SARS-CoV-2 antigen
& antibody tests for
professionals

Own internet
shop + Amazon

Pharmacies

Various retail
channel
partners

Private Users

Professional users

(Purchasing cooperations, senior
homes, hospitals, physicians,
pharmacies)




News 2020 / 2021 – NN6

2018 Break-even

- ▶ 10. März 2020: Sales start SARS-CoV2-Antibody-Test
- ▶ 30. März 2020: Capital increase 10 %
- ▶ 22. September 2020: Sales start SARS-CoV2- Antigen-Test
- ▶ 30. Oktober 2020: Order 6 Mio. Euro
- ▶ 03. November 2020: Order 8,5 Mio. Euro
- ▶ 17. November 2020: Order 14,5 Mio. Euro
- ▶ 02. Dezember 2020: Order > 20 Mio. Euro
- ▶ 10. Dezember 2020: Own SARS-CoV2 Antigen-Test „NanoRepro“ Brand
- ▶ 23. Dezember 2020: Capital increase € 8.00 Mio
- ▶ 07. Januar 2021: Application Corona-Antigentest for consumers
- ▶ 11. Februar 2021: NanoRepro turnover 10 times higher with record results for 2020
- ▶ 25. Februar 2021: Large order about 30 Mio. EUR and potential for additional 100 Mio. EUR
- ▶ 26. Februar 2021: COVID-19-Antigen-Test received approval of Paul-Ehrlich-Institute


27.08.2021: Viomed Group purchased large number of shares; merger is in process.....

04




Relevant issues for market entry

05




POC, new customer segments,
private large cooperations

06




How to manage DACH
region distributors with
success? Do's and don'ts






Relevant issues for market entry



POC, new customer segments,
private large cooperations



How to manage DACH
region distributors with
success? Do's and don'ts





04

Relevant issues for market entry



“

Especially in the areas of sales, marketing & services, the development of digital formats has been massively accelerated by COVID-19, with extensive effects in the next few years.


Digital interaction with important target groups in the health care sector such as doctors, purchasing, medical technology, nursing staff and payers is becoming the standard in medical technology sales.

Georg Stadler, Ex-Chairman Lohmann & Rauscher

”

Source: Trend Report 2021; Medizintechnik; Spectaris; R. Berger; Medical Mountains

1. Digital sales and services are increasing




- Limited access of sales reps and technicians to all type of care providers
- Webinars widely accepted for trainings of health professionals
- Sales staff and partners need training and support



New sales and communication culture requested



2. Exhibitions will be replaced by digital formats




- Reduced number of participants at key events, e.g. MEDICA
- Less chances for direct contacts with users and partners
- Local events stay important



Reviewed resource allocation and optimization of the relationship building

3. Accelerated process digitization in medical technology and hospitals




- Different status and speed in DACH region
- Awareness for digital processes further increased




Seamless internal cooperation between all stakeholders mandatory


DiGA – New option to short-cut the pathway to German reimbursement system for data-driven MDs (class I, IIa) with proven patient benefits



Source: Federal Institute for Drugs and Medical Devices (BfArM); hih - health innovation hub 2020



4. Accelerated market consolidation




- Visible in health care provision **and** medtech industry
- New EU MDR and MepV (Swiss) since Mai 2021 valid
- Mutual Recognition Agreement, MRA no longer valid!
- Improved competition pressure for SMEs
- Income situation of health insurances under stress
- Market shakeout



Opportunities for survivors!
Challenges especially in/for Switzerland



5. IVD, robotic/automation and sensor technique are the winners



- Covid-19 caused a boom in the IVD sector
- Robotic and automation is expected to improve the efficiency
- Leading HC providers count on technologies to balance the lack of personal



Improved awareness for usefulness of
selected technologies to guarantee the
quality of care

The 'NEW NORMAL' specifies winners and losers

The Conquerors

Companies that manage through digital excellence, competence and qualified specialists to succeed in opening up new markets and customer segments.

The Keepers

They can defend their previous market position by taking advantage of the opportunities offered by digitization more or less efficiently.

The Latecomers

Mainly SMEs. They clearly count to the companies that suffer from the pandemic and the increasing regulatory burden.





05

POC, new customer segments,
private large cooperations



Selected hospital groups as key clients for various diagnostics


Position	Company	No. of POCs*/beds	Employees (ø)	Turnover (mio €)	Ownership	Regional Coverage
1	Helios Group	225/28.380	53.423	5.940,00	private	DE, ES
2	Asklepios	160/27.090	36.265	3.537,30	private	DE
3	Sana Kliniken AG	103/11.331	30.638	2.841,20	private	DE
4	BG Kliniken	12/4.694	14.517	1.447,70	public (insurance)	DE
7	Agaplesion	57/6.255	20.411	1.288,90	NGO	DE
14	Ameos	95 /9.000	13.300	880	private	DE, A, CH
-	Vamed	58	19.226	2.067,00	private	A, DE, CH, Czech
-	Hirslanden	39/1.904	10.711	1.796 CHF	private	CH, UAE, NAM,ZAF

*POCs: Hospitals, out-patient clinics, MVZ, rehabilitation centers, competence centers

Source: Bibliomed ; Klinikranking 2019; <https://www.bibliomedmanager.de/klinikranking/fw-curacon-klinikranking-2021>; combined with own researches



1. Example – Helios Group & Vamed as part of Fresenius



Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA
¹ Before special items

As of December 2020



1. Example – Helios Group & VAMED

Helios Group	
Helios Germany	Quironsalud Spain
89 hospitals	52 hospitals
130 health centres(MVZ)	70 health centres
6 prevention centres	300 occupational health units
In-patient: 1,1 million out-patient: 4,1 million	In-patient: 0,9 million Out-patient: 14,1 million
73.000 employees 6,3 bill. € in 2020	40.000 employees 3,5 bill.€ in 2020

VAMED	
Prevention & health tourism	VAMED Vitality World with 8 Health Resorts Occupational health management in companies Occupational health centre
Acute and specialized care	6 Health centres and hospitals, Austria 3 Clinics in Germany, CzechRep
Rehabilitation	16 clinics in Austria 3 clinics in Switzerland 1 clinic in Czech 20 units in Germany
	19.226 employees 2,1 bill. € in 2020 (-6,3%)



2. Example – Sana Group AG

103 Clinics in Germany

- Clinic, majority ownership
- Clinic, minority ownership
- Clinic, managed by Sana
- Care home, majority owner

Stand: Januar 2021

Others:


- 4 Care homes
- 28 Medical service centres (MVZ)
- 30 Medical shops




Services for external Clients

- **Purchasing & Logistic** (> 600 clients; health service providers in Germany and Switzerland (e.g. Hirslanden Clinic Group))
- **Purchasing volume: 2,3 bill € p.a.**
- All technical Services (AEMP, Samedis platform)
- Medical Service Consulting
- Construction and Maintenance
- Cleaning, Security and Transport
- Catering

Purchasing services for Hirslanden Clinic Group since 2018



3. Hirslanden - Largest Private Swiss Hospital Group



Source: www.medinside.ch; published 17.09.2018; Hirslanden-Gruppe reorganisiert Klinik-Struktur



Centre for preventive medicine and diagnostics, Zürich

- Customised check-ups for men and women
- Cardiovascular examinations
- Preventive cancer screenings
- Comprehensive laboratory diagnostics
- Genetic analyses
- General internal medicine
- Cardiology
- Medical Family Office
- Second opinion services
- Telemedicine



Cooperation with Medbase AG
(outpatient services, pharmacies, health insurances)



4. IVD – The 5 biggest players in Germany

Company	Locations in Germany	Turnover in mio € in Germany	Turnover development	Remarks
amedes	65	2018: 364 2017: 354	+ 3%	Incl. purchasing services for physicians
LADR	86	2017: 243 2015: 220	+11%	Presence in Finland, RUS, Pol, Romania
Limbach Gruppe	32	2016: 644 2014: 455	+41%	
Sonic Healthcare	58	2018: 734 2016: 591	+24%	Purchased 2016 Staber laboratories
Synlab	65	2015: 405 2013: 382	+6%	Global player

Source: Branchenanalyse Laboranalytik; 2016; updated 2020




A network of more than
1,000
medical experts



Approx.
500 million
test results per annum

Ranked
1st – 3rd
in all key markets



SYNLAB AT A GLANCE

The SYNLAB Group is the uncontested leader on the European market for medical diagnostic services offering a full range of medical laboratory services for patients, practicing doctors, clinics and the pharmaceutical industry.

EurAsiaGrowth

Consulting-Training-Services

5. Synlab - Europe's Number One

Present in more than
40 countries on
4 continents



Areas of expertise: human,
veterinary, environment, pharma,
food, hygiene and products

Sales revenues of approx.
EUR 1.9 BILLION

More than
20,000
employees

Locations 2020


Germany: 48
Austria: 9 labs, region Vienna
Switzerland: 15 labs + 12
sampling spots

Service sectors

All type of medical IVD
diagnostics for human and
animal health

Environmental, food and other tests

in cooperation with SGS
Germany GmbH



So funktioniert der Darmflora-Test

6. POC - Biomes NGS GmbH

1 Du entnimmst deine P

Dein Testkit enthält alles, was du brauchst. Eine winzige Menge

2 Wir analysieren deine

Mithilfe der NGS-Methode wird analysiert.

3 Du erkundest online

Erkunde die Auswertung deiner Informationen und Empfehlungen online in einem geschützten Bereich.

Target clients: Consumers

Product: deep analysis of the microbiome; food supplement

Sales partners: Nutritionists, naturopaths, trainers, health therapists, occupational health specialists

Scientific partners: Charité, Carl-Thiem-Klinikum Cottbus, University Vienna, TU Wildau, Universidad Bernardo O'Higgins

Status: Established 2017; not yet profitable; actual about 20.000 clients

Cost/test: 150 €





06

How to manage DACH region distributors with success? Do's and don'ts



Key Rules of Successful Channel Partner Management



Ensure in each
Target Market Your
Partner Matches
Your Channel
Strategy


01



Selection process

- Select distributors / channel partners – don't let them select you
- Be prepared to have various type of partners in the DACH region
- Look for capabilities to develop markets together

02



Communication

- Establish simple communication routines
- Develop together new ways of communication channels with the various product users

03



Support and Networking

- Establish long-term partnerships
- Support market entry with money, managers and proven sales/marketing tools
- Build links among national partners

04




Controlling

- Fix concrete and measurable goals for sales and marketing
- Establish a practical reporting system




Wishes from Your partners...




To be part of the future innovation process is important for us.

It help us to motivate our staff members as well!




We expect to provide input to the channel strategy of our suppliers.

Channel conflicts kill our business.




We appreciate, if our future partner listen better and respect the situation in our country, e.g. pricing, quality expectations, business model.



Sometimes we feel alone if difficulties with products or clients occur.

Support in challenging customer situations is essential.



Awareness for the high competition pressure in DACH markets.

I also expect that the company knows the ecosystem of the markets and its rules.



THANK YOU

Christine Grumbach
EurAsiaGrowth
Profil.grumbach@t-online.de
Mobile +49 171 8893 000

